» Articles » PMID: 38259671

Study of MiRNA and Lymphocyte Subsets As Potential Biomarkers for the Diagnosis and Prognosis of Gastric Cancer

Overview
Journal PeerJ
Date 2024 Jan 23
PMID 38259671
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The aim of this study was to identify the expression of miRNA and lymphocyte subsets in the blood of gastric cancer (GC) patients, elucidate their clinical significance in GC, and establish novel biomarkers for the early diagnosis and prognosis of GC.

Methods: The expression of miRNAs in the serum of GC patients was screened using second-generation sequencing and detected using qRT-PCR. The correlation between miRNA expression and clinicopathological characteristics of GC patients was analyzed, and molecular markers for predicting cancer were identified. Additionally, flow cytometry was used to detect the proportion of lymphocyte subsets in GC patients compared to healthy individuals. The correlations between differential lymphocyte subsets, clinicopathological features of GC patients, and their prognosis were analyzed statistically.

Results: The study revealed that hsa-miR-1306-5p, hsa-miR-3173-5p, and hsa-miR-296-5p were expressed at lower levels in the blood of GC patients, which is consistent with miRNA-seq findings. The AUC values of hsa-miR-1306-5p, hsa-miR-3173-5p, and hsa-miR-296-5p were found to be effective predictors of GC occurrence. Additionally, hsa-miR-296-5p was found to be negatively correlated with CA724. Furthermore, hsa-miR-1306-5p, hsa-miR-3173-5p, and hsa-miR-296-5p were found to be associated with the stage of the disease and were closely linked to the clinical pathology of GC. The lower the levels of these miRNAs, the greater the clinical stage of the tumor and the worse the prognosis of gastric cancer patients. Finally, the study found that patients with GC had lower absolute numbers of CD3+ T cells, CD4+ T cells, CD8+ T cells, CD19+ B cells, and lymphocytes compared to healthy individuals. The quantity of CD4+ T lymphocytes and the level of the tumor marker CEA were shown to be negatively correlated. The ROC curve and multivariate logistic regression analysis demonstrated that lymphocyte subsets can effectively predict gastric carcinogenesis and prognosis.

Conclusion: These miRNAs such as hsa-miR-1306-5p, hsa-miR-3173-5p, hsa-miR-296-5p and lymphocyte subsets such as the absolute numbers of CD3+ T cells, CD4+ T cells, CD8+ T cells, CD19+ B cells, lymphocytes are down-regulated in GC and are closely related to the clinicopathological characteristics and prognosis of GC patients. They may serve as new molecular markers for predicting the early diagnosis and prognosis of GC patients.

Citing Articles

Dysregulation of systemic immunity and its clinical application in gastric cancer.

Zhang Y, Li J, Li J, Wang J Front Immunol. 2024; 15:1450128.

PMID: 39301031 PMC: 11410619. DOI: 10.3389/fimmu.2024.1450128.


A nomogram model of spectral CT quantitative parameters and clinical characteristics predicting lymphovascular invasion of gastric cancer.

Tong Y, Ye X, Chen Y, You Y, Zhang H, Chen S Heliyon. 2024; 10(7):e29214.

PMID: 38601586 PMC: 11004867. DOI: 10.1016/j.heliyon.2024.e29214.

References
1.
Xing X, Shi J, Jia Y, Dou Y, Li Z, Dong B . Effect of neoadjuvant chemotherapy on the immune microenvironment in gastric cancer as determined by multiplex immunofluorescence and T cell receptor repertoire analysis. J Immunother Cancer. 2022; 10(3). PMC: 8971786. DOI: 10.1136/jitc-2021-003984. View

2.
Zhang J, Wang H, Yuan C, Wu J, Xu J, Chen S . ITGAL as a Prognostic Biomarker Correlated With Immune Infiltrates in Gastric Cancer. Front Cell Dev Biol. 2022; 10:808212. PMC: 8987306. DOI: 10.3389/fcell.2022.808212. View

3.
Orso F, Quirico L, Dettori D, Coppo R, Virga F, Ferreira L . Role of miRNAs in tumor and endothelial cell interactions during tumor progression. Semin Cancer Biol. 2019; 60:214-224. DOI: 10.1016/j.semcancer.2019.07.024. View

4.
Wang J, Zhang M, Hu X, She J, Sun R, Qin S . miRNA-194 predicts favorable prognosis in gastric cancer and inhibits gastric cancer cell growth by targeting CCND1. FEBS Open Bio. 2021; 11(7):1814-1826. PMC: 8255842. DOI: 10.1002/2211-5463.13125. View

5.
Jiang H, Shi Z, Wang P, Wang C, Yang L, Du G . Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer. J Natl Cancer Inst. 2018; 111(4):409-418. DOI: 10.1093/jnci/djy134. View